Member Info for Richob

Agreed, Timster.

Also looks like income is increasing and loss per share decreasing and more than enough cash to finish the current trial with AVA3996 also pencilled in to start next year after IND filing.

A far better position than many had predicted and in line with previous company comments.

The update on all of the collaborations that generate the current income was particularly upbeat as well.

Onwards Avacta.

... the chat today at least we have had a few sensible points raised:

1. There is a general downward market trend related to taxes and spending as opposed to what companies deserve.
2. Avacta is less affected by this.
3. We know the company spends money each year and that they are fully funded into mid 2023.

As has been mentioned, it is the outlook for the company that is important:

A) Is the trial progressing well?
B) Is there interest in other Avacta pro drugs?
C) Are other collaborations going well?

I haven't seen anything negative about any of the above and await the update accordingly, knowing that we are approaching the end of cohort four.

My belief is that the world will want a better way of treating cancer and that Avacta can provide this.

I also doubt that many people yet know who Avacta are but that can change very quickly.

Onwards Avacta.

This also mentions greater effectiveness and greater safety under definitions.

How might they know?

Thanks for the link, icecool.

Onwards Avacta.

Not a bad shout, 54retiresoon.

AS has already said that you don't license out your lead prodrug (AVA6000) but that you do look to license out subsequent pro drugs, such as AVA3996, which must be of interest to Takeda.

Licensing is how the company currently operates and it has worked so far. I guess that any offer would therefore need to be large enough for the board to take seriously as the IP has value and potential going forward.

Well just have to wait and see and probably not for that long now.

Onwards Avacta.

... as nervous as I am, what is clear is that:

a) LG Chem are progressing ( and paying)
b ) Point Biopharma are progressing (and paying)

(see recent previous posts)

It would be difficult to think that Affyxell is not progressing:

https://avacta.com/affyxell-expands-its-strategic-partnership-with-genscript-probio/

This leaves just a couple of other little things like AVA6000 and AVA3996 to take into account.

Not really sure what the "nervous" thread is about due to the success of the green box methodology but there must be plenty of other shares where nervousness is far greater than here I would have thought.

Enjoy the remainder of the long weekend.

Onwards Avacta.

I think this is what LG Chem are now progressing following the recent license renewal:


https://jitc.bmj.com/content/10/7/e004695

Onwards Avacta.

Yes, crowfoot, S for Avacta.

Looks like Point have enough to continue their preclinical research with Avacta, gmcc.

They've agreed $9.5m for the first milestone in any event.

Can't be bad for Avacta that they have raised funds.

Onwards Avacta.

Good bye.

Checked your posting history and can't find any sensible contrition.

Obviously no need to reply as you are clearly a whatever.

Onwards Avacta.

Don't think so, riesgo.

A bankers bonus is paid on additional profits, which, in turn, generates additional tax.

My point, which you have failed to understand, is that this is the Avacta discussion board and which we should use to discuss Avacta.

The excellent post about Sophie is far more important than your or my or anybody's thoughts about banker bonuses.

If you want to continue to discuss other things just green box me please.

Good luck to you.

Onwards Avacta.

Riesgo,

I think you missed the point of my post.

The Sophie post is far more relevant.

Good luck.

Onwards Avacta.

Riesgo,

Debating bankers bonuses is an option or we can concentrate on Avacta.

Let me know.

Good find, ES.

Onwards Avacta.

The price of milk these days, doctor. Ridiculous really.

I think we all remember that day !

... seems to know Takeda:

https://www.cambridgeindependent.co.uk/business/f-star-therapeutics-and-takeda-strike-immuno-oncology-deal-t-9265763/

Onwards Avacta.

risk,

I doubt he would have been allowed to say anything else without giving too much away.

In any event, progress has been made since the application.

Onwards Avacta.

Looks like Orphan Drug Status can take up to 90 days to be granted.

That means that an application went in from the 6th June onwards and well before cohort four in any event.

If the FDA were happy before cohort four then it bodes well for the progress being made and the data that goes with that.

Onwards Avacta.

Your knowledge of the company is astounding, simba.

Good luck.

Onwards Avacta.

gmcc,

Looks like $9.5m for the first one and then $8.5m for all other ones plus royalties on sales plus the annual $2m licensing fee.

Onwards Avacta.

I believe it is per product, gmcc:

https://avacta.com/license-agreement-with-point-biopharma-inc/

Onwards Avacta.